Seragon touts promising preclinical lifespan and healthspan data in mice

Treated mice had increased expression of longevity-associated genes and enhanced endurance and reduced frailty scores compared with controls.

Mysterious longevity biotech Seragon Biosciences is claiming significant results in a preclinical study of its “anti-aging candidate” known only as SRN-901. The Irvine, California-based biopharma quietly issued a press release earlier this week indicating that its 300-mouse study demonstrated “one of the largest extensions of lifespan and healthspan to date” in treated animals.

Little information is available about Seragon or SRN-901, but the company said that whole-genome transcriptome sequencing of mice treated in the study revealed increased expression of longevity-associated genes and reduced expression of aging-related genes. The company also claims that a metabolic panel displayed “beneficial changes” in biomarkers associated with a younger biological age.

In addition to lifespan, Seragon says its study evaluated SRN-901’s effects on healthspan, physical, and cognitive function. Elderly mice treated with SRN-901 exhibited enhanced endurance and reduced frailty scores compared with controls, and there was also a significant decrease in tumor occurrence among the treated group.

With a stated goal of “improving human and animal health through innovative science”, Seragon’s website indicates the company is working in areas including aging, metabolism, gene therapy, and bioinformatics. The site also gives some clues as to the potential approach behind SRN-901:

“Our techniques include determining biomarkers correlating with age and developing gene therapy vectors to restore their functions in genomic analysis. Our investigations additionally address research in molecules and mechanisms associated with metabolism, such as regulators of the mammalian target of rapamycin (mTOR) and nicotinamide adenine dinucleotide (NAD+) pathways.”

Seragon says it plans to conduct further analysis of the study data and will publish its findings once completed. We look forward to seeing a lot more information before we start getting excited about this one.

Photograph: LightFieldStudios/Envato